



María Francisca Cano Abad, PhD

Lecture of Pharmacology

Pharmacology Department

Instituto de Investigación Sanitaria, Hospital de la Princesa

Instituto Teófilo Hernando for Drug Discovery

Universidad Autónoma de Madrid,

Madrid, Spain

▪ **RESEARCH INTEREST**

1. **Calcium signaling.**
2. **Neurodegenerative diseases, screening of neuroprotectant compounds.**

In the past ten years, I focused on the regulation of the calcium channel named CALHM1 “Calcium Homeostasis Modulator 1”. First, CALHM1 was involved as a risk factor in **Alzheimer disease**; however, its role on the pathophysiology of this disease is controversial, and upon revision. From its physiological point of view, CALHM1 play a role in the taste pathway of the sweet, salt and human. In addition, it is a voltage dependent channel that its opening regulates the neuronal action potential. For this reason my work hypothesis in which I am working on, is to clarify whether CALHM1 its implicated on the propagation of neuronal death in the stroke. **Pharmacology of CALHM1 with potential therapeutic application in neurodegenerative diseases and stroke.** In 2015, I published a paper showing that a compound called CGP was able to modulate CALHM1, using the HeLa cells as a model. CGP and its derivate could be a potential neuroprotective compounds and with potential therapeutic applications to neurodegenerative diseases (particularly Alzheimer’s disease) and cerebrovascular diseases (stroke). **Research focus.** I would focus the basic research on the understanding of the role of CALHM1 and the mitochondrial sodium/calcium exchanger in ischemia and neurodegenerative diseases. In addition, I will try to develop newly synthesized compounds as **neuroprotective medicines for Alzheimer’s disease and ischemia**, taking as model the mitochondrial sodium/calcium exchanger as goal of the neuroproteccion.

▪ **RECENT PUBLICATIONS**

De Los Rios C, **Cano-Abad MF**, Villarroja M, López MG. **Chromaffin cells as a model to evaluate mechanisms of cell death and neuroprotective compounds.** *Pflugers Arch.* 2018. 470(1):187-198.

Martin-de-Saavedra MD, Navarro E, Moreno-Ortega AJ, Cunha MP, Buendia I, Hernansanz-Agustín P, León R, **Cano-Abad MF**, Martínez-Ruiz A, Martínez-Murillo R, Duchon MR, López MG. **The APPsw/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca(2+) dysregulation, and mitochondrial abnormalities.** *J Neurochem.* 2018. 145(2):170-182.

Moreno-Ortega AJ, Al-Achbili LM, Alonso E, de Los Ríos C, García AG, Ruiz-Nuño A, **Cano-Abad MF.** **Neuroprotective Effect of the Novel Compound ITH33/IQM9.21 Against Oxidative Stress and Na(+) and Ca(2+) Overload in Motor Neuron-like NSC-34 Cells.** *Neurotox Res.* 2016; 3:380-91.

Mouhid Al-Achbili L, Moreno-Ortega AJ, Matías-Guiu J, **Cano-Abad MF**, Ruiz-Nuño A. **ITH33/IQM9.21 provides neuroprotection in a novel ALS model based on TDP-43 and Na(+)/Ca(2+) overload induced by VTD.** *Neurosci Lett.* 2016: 9:633:28-32.

Moreno-Ortega, A. J., Buendia I, Mouhid L, Egea J, Lucea S., Ruiz-Nuño A, López M. G and **Cano-Abad MF.** **CALHM1 and its polymorphism P86L differentially control Ca²⁺ homeostasis, mitogen-activated protein kinase signalling and cell vulnerability upon amyloid beta exposure.** *Aging Cell.* 14: 1094-1102. 2015.

Martínez-Sanz FJ., Lajarín-Cuesta R., González-Lafuente L., Moreno-Ortega AJ., Punzón E., **Cano-Abad MF.**, and De los Ríos C. **Neuroprotective profile of pyridothiazepines with blocking activity of the mitochondrial Na⁺/Ca²⁺ exchanger.** *Eur. J. Med. Chem.* 2016; 109: 114-23.

Martínez-Sanz FJ., Lajarín-Cuesta R., Moreno-Ortega AJ., González-Lafuente L., Fernández-Morales JC., López-Arribas R., **Cano-Abad MF.**, and de los Ríos C. **Benzothiazepine CGP37157 Analogues Exert Cytoprotection in Various in Vitro Models of Neurodegeneration.** *ACS Chem Neurosci.* 2015. 6:1626-36

Moreno-Ortega AJ, Martínez-Sanz FJ, Lajarín-Cuesta R, de Los Rios C, **Cano-Abad MF.** **Benzothiazepine CGP37157 and its 2'-isopropyl analogue modulate Ca(2+) entry through CALHM1.** *Neuropharmacology.* 2015. 95:503

Guerra-Álvarez M, Moreno-Ortega AJ, Navarro E, Fernández-Morales JC, Egea J, López MG, **Cano-Abad MF.** **Positive allosteric modulation of alpha-7 nicotinic receptors promotes cell death by inducing Ca(2+) release from the endoplasmic reticulum.** *J Neurochem.* 2015. 133(3):309-19.

Martín-Sabroso C, Fraguas-Sánchez AI, Aparicio-Blanco J, **Cano-Abad MF**, **Torres-Suárez AI.** **Critical attributes of formulation and of elaboration process of PLGA-protein microparticles.** *Int J Pharm.* 2015. 480(1-2):27-36.

Martín-Sabroso C, Moreno-Ortega AJ, Aparicio-Blanco J, Fraguas-Sánchez AI, **Cano-Abad MF**, **Torres-Suárez AI.** **Overcoming glucocorticoid resistances and improving antitumor therapies: lipid and polymers carriers.** *Pharm Res.* 2015. 32(3):968-85.

Moreno-Ortega AJ, Ruiz-Nuño A, García AG, Cano-Abad MF. **Mitochondria sense with different kinetics the calcium entering into HeLa cells through calcium channels CALHM1 and mutated P86L-CALHM1.** *Biochem Biophys Res Commun.* 2010. 391: 722-26.